Positive decision by NICE good news for breast cancer patients
The National Institute for Health and Care Excellence (NICE) has recommended Novartis’ Kisqali (ribociclib) in combination with fulvestrant for women with prior... Read More...
Are you a qualified pharmacist or health professional?
By continuing to access this site, you are consenting to viewing promotional product information provided by our pharmaceutical company sponsors